http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정상경,김경아,So Young Ha,Hyun Kyo Lee,Young Doo Kim,Bu Hyun Lee,백우현,Jong Wook Kim,Won Ki Bae,Nam-Hoon Kim,이준성,Yoon Jung Jwa 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.1
Background/Aims: This study investigated the antiviral effects of tenofovir disoproxil fumarate (TDF) monotherapy in nucleos(t)ide analogue (NA)-naive and NA-experienced chronic hepatitis B (CHB) patients. Methods: CHB patients treated with TDF monotherapy (300 mg/day) for ≥12 weeks between December 2012 and July 2014 at a single center were retrospectively enrolled. Clinical, biochemical, and virological parameters were assessed every 12 weeks. Results: In total, 136 patients (median age 49 years, 96 males, 94 HBeAg positive, and 51 with liver cirrhosis) were included. Sixty-two patients were nucleos(t)ide (NA)-naïve, and 74 patients had prior NA therapy (NA-exp group), and 31 patients in the NA-exp group had lamivudine (LAM)-resistance (LAM-R group). The baseline serum hepatitis B virus (HBV) DNA level was 4.9±2.3 log IU/mL (mean±SD ), and was higher in the NA-naïve group than in the NA-exp and LAM-R groups (5.9±2.0 log IU/mL vs 3.9±2.0 log IU/mL vs 4.2±1.7 log IU/mL, P<0.01). The complete virological response (CVR) rate at week 48 in the NA-naïve group (71.4%) did not differ significantly from those in the NA-exp (71.3%) and LAM-R (66.1%) groups. In multivariate analysis, baseline serum HBV DNA was the only predictive factor for a CVR at week 48 (hazard ratio, 0.809; 95% confidence interval, 0.729–0.898), while the CVR rate did not differ with the NA experience. Conclusions: TDF monotherapy was effective for CHB treatment irrespective of prior NA treatment or LAM resistance. Baseline serum HBV DNA was the independent predictive factor for a CVR. (Clin Mol Hepatol 2015;21:41-48)
Etanercept으로 치료한 류마티스관절염 환자에서 발생한 악성 림프종 1예
정상경 대한내과학회 2009 대한내과학회지 Vol.77 No.-
Rheumatoid arthritis (RA) is a chronic inflammatory polyarthritis that is associated with an increased risk of coronary artery disease, infection, lymphoma, and life expectancy. Several studies have shown that patients with RA have a 2~3x increased risk of developing lymphomas as compared with the general population. TNF-α antagonist therapy might be independently associated with an increased risk of lymphoma; however, other studies have shown that the risk of lymphoma is increased in RA patients with severe disease activity rather than the treatment per se. We experienced a 65-year-old woman who developed Etanercept–associated malignant lymphoma with rheumatoid arthritis. (Korean J Med 77:S1342-S1346, 2009) 1998년 이래로 TNF-α 길항제는 중증 류마티스 관절염의 치료에 탁월한 치료 효과와 함께 비교적 안전하게 널리 치료제로 이용되고 있다. 그러나 악성 림프종 발생 위험을 높인다는 많은 보고들과 함께, 악성 림프종 발생이 치료제 자체보다는 류마티스관절염의 질병 활성도와 더 큰 상관관계가 있다는 주장도 제기되고 있는 상태이다. 본 저자들은 아직까지 국내에 보고가 드문 etanercept로 치료한 류마티스관절염 환자에서 발생한 악성 림프종을 경험하여 참고문헌과 함께 보고하는 바이다.
정상경,Jeong, Sang-Gyeong 대한석유협회 1993 석유와 에너지 Vol.1993 No.4
이 논문은 지난 3월 24일 상공회의소에서 열린 자원경제학회 주최의 자원경제학회 주최의 자원ㆍ환경과 신산업정책에 관한 정책토론회에서 발표된 내용을 옮긴 것이다.
간경변 환자에서 발생한 Hafnia alvei에 의한 자발성 복막염 1예
정상경,이준성,김경아,김영두,좌윤정,김나경,곽이경 대한감염학회 2010 Infection and Chemotherapy Vol.42 No.6
Hafnia alvei is a gram-negative bacillus that is rarely isolated from human clinical specimens and is rarely pathogenic. This organism is an extremely uncommon cause of spontaneous bacterial peritonitis (SBP). We report a case of an 83-year-old male with hepatitis C-associated liver cirrhosis and hepatocellular carcinoma who was diagnosed with SBP caused by H. alvei. He was admitted to an university-affiliated hospital with fever and abdominal pain. There were 2 episodes of SBP during 2months. Although isolates of H. alvei from ascitic fluid were shown to be susceptible to cefotaxime, responses for cefotaxime treatment were inadequate in both episodes. Therefore, cefotaxime was switched to imipenem in the first episode and to ciprofloxacin in the second, according to the results of antimicrobial susceptibility. After the antibiotics was changed, SBP was resolved.